Celator Pharmaceuticals Inc. (NASDAQ:CPXX)’s share price was down 0% on Friday . The stock traded as low as $30.23 and last traded at $30.24, with a volume of 274,314 shares traded. The stock had previously closed at $30.25.

Several equities analysts have recently weighed in on CPXX shares. HC Wainwright lifted their target price on shares of Celator Pharmaceuticals to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, March 15th. Roth Capital lifted their target price on shares of Celator Pharmaceuticals from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday, March 15th. Janney Montgomery Scott started coverage on shares of Celator Pharmaceuticals in a research note on Tuesday, March 15th. They issued a “buy” rating and a $13.00 target price for the company. Needham & Company LLC started coverage on shares of Celator Pharmaceuticals in a research note on Tuesday, April 12th. They issued a “buy” rating and a $24.00 target price for the company. Finally, Stifel Nicolaus started coverage on shares of Celator Pharmaceuticals in a research note on Friday, April 22nd. They issued a “buy” rating and a $23.00 target price for the company. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Celator Pharmaceuticals has an average rating of “Hold” and a consensus price target of $18.67.

The firm has a 50 day moving average price of $27.92 and a 200 day moving average price of $12.13. The firm’s market capitalization is $1.28 billion.

Celator Pharmaceuticals (NASDAQ:CPXX) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.01. Equities research analysts predict that Celator Pharmaceuticals Inc. will post ($0.62) earnings per share for the current year.

Celator Pharmaceuticals, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company’s technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.